2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal Of Biological Psychiatry 2022, 24: 118-134. PMID: 35900217, DOI: 10.1080/15622975.2022.2086296.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsRepetitive transcranial magnetic stimulationCognitive behavioral therapyFirst-line treatmentDeep brain stimulationSSRI treatmentBiological Psychiatry (WFSBP) GuidelinesSecond-line medicationsNon-pharmacological treatmentSerotonin reuptake inhibitorsNon-pharmacological interventionsTreatment-resistant casesTranscranial magnetic stimulationWorld FederationTreatment of anxietyPosttraumatic stress disorderTreatment of OCDReuptake inhibitorsMedication treatmentPharmacological treatmentSNRI venlafaxineInternet-CBTConsensus panelMagnetic stimulationBrain stimulationManagement of Patients With Obsessive-Compulsive Disorder: Focus on Pharmacotherapy
Maziero M, Macaya D, Shavitt R, Diniz J, Miguel E, Silva R, Costa D. Management of Patients With Obsessive-Compulsive Disorder: Focus on Pharmacotherapy. Psychiatric Annals 2022, 52: 143-151. DOI: 10.3928/00485713-20220315-01.Peer-Reviewed Original ResearchSelective serotonin reuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentFirst-line pharmacological therapySecond-line pharmacological treatmentPotential clinical situationsHalf of patientsManagement of patientsSerotonin reuptake inhibitorsKnowledge of cliniciansCommon clinical issueTreatment of patientsReports of RCTsTreatment of OCDAdverse eventsSSRI treatmentPharmacological therapyReuptake inhibitorsSignificant morbidityPharmacological strategiesLimited efficacyClinical practiceClinical situationsClinical issuesSocial disability
2021
The impact of generalized anxiety disorder in obsessive-compulsive disorder patients.
Sharma P, Rosário M, Ferrão Y, Albertella L, Miguel E, Fontenelle L. The impact of generalized anxiety disorder in obsessive-compulsive disorder patients. Psychiatry Research 2021, 300: 113898. PMID: 33812219, DOI: 10.1016/j.psychres.2021.113898.Peer-Reviewed Original ResearchConceptsGeneralized anxiety disorderObsessive-compulsive disorderComorbid generalized anxiety disorderAnxiety disordersOnset of OCDType II bipolar disorderDiagnosis of GADTreatment of OCDObsessive-compulsive disorder patientsSevere anxiety symptomsMann-Whitney U testChi-square testPrevalent comorbiditiesClinical profileClinical severityMood disordersDisorder patientsComorbid anxietyPanic disorderBipolar disorderAvoidant behaviorComorbiditiesGreater suicidalityLogistic regressionU test
2017
Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle
Reimer A, de Oliveira A, Diniz J, Hoexter M, Miguel E, Milad M, Brandão M. Fear extinction in an obsessive-compulsive disorder animal model: Influence of sex and estrous cycle. Neuropharmacology 2017, 131: 104-115. PMID: 29225044, DOI: 10.1016/j.neuropharm.2017.12.015.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderFear extinctionOCD patientsTreatment of OCDFear extinction retentionExtinction retention deficitsFear extinction trainingOCD pathophysiologyOCD-like symptomsAnterior cingulate cortexFear inhibitionExtinction retentionAccount sex differencesEstrous cycleExtinction trainingRetention deficitsRepetitive behaviorsDistinct neurotransmitter systemsMedial prefrontalUntreated OCD patientsCingulate cortexAnimal modelsSelf-grooming behaviorBrain areasEstrous cycle phase
2016
Use of benzodiazepines in obsessive–compulsive disorder
Starcevic V, Berle D, do Rosário M, Brakoulias V, Ferrão Y, Viswasam K, Shavitt R, Miguel E, Fontenelle L. Use of benzodiazepines in obsessive–compulsive disorder. International Clinical Psychopharmacology 2016, 31: 27-33. PMID: 26426443, DOI: 10.1097/yic.0000000000000100.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Anxiety AgentsAnxietyBenzodiazepinesCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSocioeconomic FactorsConceptsObsessive-compulsive disorderBDZ useOCD patientsUse of benzodiazepinesTreatment of OCDBrazilian Research ConsortiumAdditional medicationTreatment guidelinesMulticentre studyReuptake inhibitorsObsessive-compulsive spectrum disordersBenzodiazepine useMarked anxietyPatientsMedicationsBDZDisordersResearch ConsortiumCurrent age